Skip to main content
Erschienen in: Annals of Surgical Oncology 13/2019

16.09.2019 | Translational Research and Biomarkers

Comprehensive Exploration to Identify Predictive DNA Markers of ΔNp63/SOX2 in Drug Resistance in Human Esophageal Squamous Cell Carcinoma

verfasst von: Yosuke Ooizumi, MD, Keita Kojima, MD, Kazuharu Igarashi, MD, Yoko Tanaka, MD, Hiroki Harada, MD, Kazuko Yokota, MD, Takeshi Kaida, MD, Satoru Ishii, MD, PhD, Toshimichi Tanaka, MD, PhD, Keigo Yokoi, MD, PhD, Nobuyuki Nishizawa, MD, PhD, Marie Washio, MD, Hideki Ushiku, MD, PhD, Hiroshi Katoh, MD, PhD, Yoshimasa Kosaka, MD, PhD, Hiroaki Mieno, MD, PhD, Kei Hosoda, MD, PhD, Masahiko Watanabe, MD, PhD, FACS, Chikatoshi Katada, MD, PhD, Naoki Hiki, MD, PhD, Keishi Yamashita, MD, PhD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 13/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

OBP-801 is a novel histone deacetylase inhibitor being developed as an anticancer drug. In this study, we explored genes to predict drug resistance in human cancer.

Methods

OBP-801 resistance was assessed in 37 strains of human cancer cell lines. Expression microarrays harboring 54,675 genes were used to focus on candidate genes, which were validated for both functional and clinical relevance in esophageal squamous cell carcinoma (ESCC).

Results

OBP-801 is sensitive to esophageal, gastric, and thyroid cancer, and resistant to some esophageal and colorectal cancers. We therefore used ESCC to explore genes. Comprehensive exploration focused on ΔNp63/SOX2, which were both genetically and epigenetically overexpressed in ESCC. Genomic amplifications of ΔNp63/SOX2 were tightly correlated each other (r = 0.81). Importantly, genomic amplification of ΔNp63/SOX2 in the resected tumors after neoadjuvant chemotherapy was significantly associated with histological grade of response (G1). Forced expression of either of these two genes did not induce each other, suggesting that their functional relevances were independent and showed robust drug resistance in OBP-801, as well as 5-fluorouracil. Furthermore, ΔNp63 could exert a potent oncogenic potential. RNA interference of ΔNp63 supported its oncological properties, as well as drug resistance.

Conclusion

Comprehensive exploration of genes involved in anticancer drug residence could identify critical oncogenes of ΔNp63/SOX2 that would predict chemotherapy response in ESCC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Shindoh N, Mori M, Terada Y, Oda K, et al. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. Int J Oncol. 2008;32(3):545–55.PubMed Shindoh N, Mori M, Terada Y, Oda K, et al. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. Int J Oncol. 2008;32(3):545–55.PubMed
2.
Zurück zum Zitat Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37(4):391–400.CrossRef Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37(4):391–400.CrossRef
3.
Zurück zum Zitat Huang BH, Laban M, Leung CH, Lee L, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005;12(4):395–04.CrossRef Huang BH, Laban M, Leung CH, Lee L, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005;12(4):395–04.CrossRef
4.
Zurück zum Zitat Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Göttlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004;5(5):455–63.CrossRef Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Göttlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004;5(5):455–63.CrossRef
5.
Zurück zum Zitat Wilson AJ, Byun DS, Popova N, Murray LB, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and arederegulated in human colon cancer. J Biol Chem. 2006;281(19):13548–58.CrossRef Wilson AJ, Byun DS, Popova N, Murray LB, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and arederegulated in human colon cancer. J Biol Chem. 2006;281(19):13548–58.CrossRef
6.
Zurück zum Zitat Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1(4):287–99.CrossRef Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1(4):287–99.CrossRef
7.
Zurück zum Zitat Minucci S, Pelicci P. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6(1):38–51.CrossRef Minucci S, Pelicci P. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6(1):38–51.CrossRef
8.
Zurück zum Zitat Kelly WK, O’Connor OA, Krug LM, Chiao JH, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23(17):3923–31.CrossRef Kelly WK, O’Connor OA, Krug LM, Chiao JH, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23(17):3923–31.CrossRef
9.
Zurück zum Zitat O’Connor OA, Heaney ML, Schwartz L, Richardson S, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24(1):166–73.CrossRef O’Connor OA, Heaney ML, Schwartz L, Richardson S, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24(1):166–73.CrossRef
10.
Zurück zum Zitat Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25:84–90.CrossRef Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25:84–90.CrossRef
11.
Zurück zum Zitat Kikuchi M, Yamashita K, Waraya M, Minatani N et al. Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer. Oncotarget. 2016;7(2):1741–53.CrossRef Kikuchi M, Yamashita K, Waraya M, Minatani N et al. Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer. Oncotarget. 2016;7(2):1741–53.CrossRef
12.
Zurück zum Zitat Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M. Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma. Int J Cancer. 2010;127(3):543–54.CrossRef Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M. Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma. Int J Cancer. 2010;127(3):543–54.CrossRef
13.
Zurück zum Zitat Ooki A, Yamashita K, Kikuchi S, et al. Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer. BMC Cancer. 2011;11:122.CrossRef Ooki A, Yamashita K, Kikuchi S, et al. Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer. BMC Cancer. 2011;11:122.CrossRef
14.
Zurück zum Zitat Yokoi K, Yamashita K, Ishii S, Tanaka T, et al. Comprehensive molecular exploration identified promoter DNA methylation of the CRBP1 gene as a determinant of radiation sensitivity in rectal cancer. Br J Cancer. 2017;116(8):1046–56.CrossRef Yokoi K, Yamashita K, Ishii S, Tanaka T, et al. Comprehensive molecular exploration identified promoter DNA methylation of the CRBP1 gene as a determinant of radiation sensitivity in rectal cancer. Br J Cancer. 2017;116(8):1046–56.CrossRef
15.
Zurück zum Zitat Waraya M, Yamashita K, Katoh H, et al. Cancer specific promoter CpG Islands hypermethylation of HOP homeobox (HOPX) gene and its potential tumor suppressive role in pancreatic carcinogenesis. BMC Cancer. 2012;12:397.CrossRef Waraya M, Yamashita K, Katoh H, et al. Cancer specific promoter CpG Islands hypermethylation of HOP homeobox (HOPX) gene and its potential tumor suppressive role in pancreatic carcinogenesis. BMC Cancer. 2012;12:397.CrossRef
16.
Zurück zum Zitat Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18–43. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18–43.
17.
Zurück zum Zitat Cancer Genome Atlas Research Network, Analysis Working Group, Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75. Cancer Genome Atlas Research Network, Analysis Working Group, Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75.
18.
Zurück zum Zitat Bass AJ, Watanabe H, Mermel CH, Yu S, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41(11):1238–42.CrossRef Bass AJ, Watanabe H, Mermel CH, Yu S, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41(11):1238–42.CrossRef
19.
Zurück zum Zitat Watanabe H, Ma Q, Peng S, Adelmant G, et al. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest. 2014;124(4):1636–45.CrossRef Watanabe H, Ma Q, Peng S, Adelmant G, et al. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest. 2014;124(4):1636–45.CrossRef
20.
Zurück zum Zitat Boumahdi S, Driessens G, Lapouge G, Rorive S, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014;511(7508):246–50.CrossRef Boumahdi S, Driessens G, Lapouge G, Rorive S, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014;511(7508):246–50.CrossRef
21.
Zurück zum Zitat Siegle JM, Basin A, Sastre-Perona A, Yonekubo Y, et al. SOX2 is a cancer-specific regulator of tumour initiating potential in cutaneous squamous cell carcinoma. Nat Commun. 2014;31(5):4511.CrossRef Siegle JM, Basin A, Sastre-Perona A, Yonekubo Y, et al. SOX2 is a cancer-specific regulator of tumour initiating potential in cutaneous squamous cell carcinoma. Nat Commun. 2014;31(5):4511.CrossRef
22.
Zurück zum Zitat Huang H, Zhang W, Pan Y, Gao Y, et al. YAP Suppresses lung squamous cell carcinoma progression via deregulation of the DNp63-GPX2 axis and ROS accumulation. Cancer Res. 2017;77(21):5769–81.CrossRef Huang H, Zhang W, Pan Y, Gao Y, et al. YAP Suppresses lung squamous cell carcinoma progression via deregulation of the DNp63-GPX2 axis and ROS accumulation. Cancer Res. 2017;77(21):5769–81.CrossRef
23.
Zurück zum Zitat Tanaka T, Kojima K, Yokota K, et al. Comprehensive genetic search to clarify the molecular mechanism of drug resistance identifies ASCL2-LEF1/TSPAN8 axis in colorectal cancer. Ann Surg Oncol. 2019;26(5):1401–11.CrossRef Tanaka T, Kojima K, Yokota K, et al. Comprehensive genetic search to clarify the molecular mechanism of drug resistance identifies ASCL2-LEF1/TSPAN8 axis in colorectal cancer. Ann Surg Oncol. 2019;26(5):1401–11.CrossRef
24.
Zurück zum Zitat Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA. 2000;97(10):5462–7.CrossRef Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA. 2000;97(10):5462–7.CrossRef
25.
Zurück zum Zitat Campbell JD, Yau C, Bowlby R, Liu Y, et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep. 2018;23(1):194–212.CrossRef Campbell JD, Yau C, Bowlby R, Liu Y, et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep. 2018;23(1):194–212.CrossRef
26.
Zurück zum Zitat Yamashita K, Hosoda K, Moriya H, Katada C, et al. Prognostic advantage of docetaxel/cisplatin/5-fluorouracil neoadjuvant chemotherapy in clinical stage II/III esophageal squamous cell carcinoma due to excellent control of preoperative disease and postoperative lymph node recurrence. Oncology. 2017;92(4):221–8.CrossRef Yamashita K, Hosoda K, Moriya H, Katada C, et al. Prognostic advantage of docetaxel/cisplatin/5-fluorouracil neoadjuvant chemotherapy in clinical stage II/III esophageal squamous cell carcinoma due to excellent control of preoperative disease and postoperative lymph node recurrence. Oncology. 2017;92(4):221–8.CrossRef
27.
Zurück zum Zitat Yamashita K, Upadhyay S, Osada M, Hoque MO, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2002;2(6):485–95.CrossRef Yamashita K, Upadhyay S, Osada M, Hoque MO, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2002;2(6):485–95.CrossRef
28.
Zurück zum Zitat Ishii S, Yamashita K, Harada H, et al. The H19-PEG10/IGF2BP3 axis promotes gastric cancer progression in patients with high lymph node ratios. Oncotarget. 2017;8(43):74567–81.CrossRef Ishii S, Yamashita K, Harada H, et al. The H19-PEG10/IGF2BP3 axis promotes gastric cancer progression in patients with high lymph node ratios. Oncotarget. 2017;8(43):74567–81.CrossRef
29.
Zurück zum Zitat Osada M, Park H, Nagakawa Y, Yamashita K, et al. Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol. 2005;25(14):6077–89.CrossRef Osada M, Park H, Nagakawa Y, Yamashita K, et al. Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol. 2005;25(14):6077–89.CrossRef
30.
Zurück zum Zitat Tanaka T, Watanabe M, Yamashita K. Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. Oncotarget. 2018;9(22):16234–47.CrossRef Tanaka T, Watanabe M, Yamashita K. Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. Oncotarget. 2018;9(22):16234–47.CrossRef
31.
Zurück zum Zitat Abraham CG, Ludwig MP, Andrysik Z, et al. DeltaNp63alpha suppresses TGFB2 expression and RHOA activity to drive cell proliferation in squamous cell carcinomas. Cell Rep. 2018;24(12):3224–36.CrossRef Abraham CG, Ludwig MP, Andrysik Z, et al. DeltaNp63alpha suppresses TGFB2 expression and RHOA activity to drive cell proliferation in squamous cell carcinomas. Cell Rep. 2018;24(12):3224–36.CrossRef
32.
Zurück zum Zitat Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.CrossRef Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.CrossRef
Metadaten
Titel
Comprehensive Exploration to Identify Predictive DNA Markers of ΔNp63/SOX2 in Drug Resistance in Human Esophageal Squamous Cell Carcinoma
verfasst von
Yosuke Ooizumi, MD
Keita Kojima, MD
Kazuharu Igarashi, MD
Yoko Tanaka, MD
Hiroki Harada, MD
Kazuko Yokota, MD
Takeshi Kaida, MD
Satoru Ishii, MD, PhD
Toshimichi Tanaka, MD, PhD
Keigo Yokoi, MD, PhD
Nobuyuki Nishizawa, MD, PhD
Marie Washio, MD
Hideki Ushiku, MD, PhD
Hiroshi Katoh, MD, PhD
Yoshimasa Kosaka, MD, PhD
Hiroaki Mieno, MD, PhD
Kei Hosoda, MD, PhD
Masahiko Watanabe, MD, PhD, FACS
Chikatoshi Katada, MD, PhD
Naoki Hiki, MD, PhD
Keishi Yamashita, MD, PhD, FACS
Publikationsdatum
16.09.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 13/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07795-w

Weitere Artikel der Ausgabe 13/2019

Annals of Surgical Oncology 13/2019 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.